In Response: I thank the authors for their favorable commentary (1) related to our recently published article (2). In their commentary the authors note that the low number of chikungunya cases captured through passive surveillance underrepresents the true burden of disease in Jamaica, particularly fatal infections during the 2014 chikungunya epidemic year (3).

Underreporting of chikungunya cases in Jamaica has been acknowledged and has multiple factors (4). Most chikungunya cases are not captured through a passive clinic-based surveillance (5), and in Jamaica most case-patients likely did not seek care at the advanced public health center passive surveillance sites. In addition, real-time PCR, the most sensitive diagnostic test type during acute infection, was highly limited in Jamaica during the 2014 chikungunya epidemic. For these reasons, identification of chikungunya cases through passive surveillance was expected to represent only a small fraction of the population. It is possible that many excess deaths in Jamaica during 2014 were the result of chikungunya virus infections escaping surveillance. Chikungunya fatalities may be difficult to capture with limited surveillance capacity. Furthermore, chikungunya virus infections, particularly in the elderly, may exacerbate existing comorbidities and lead to extended hospitalization that could result in nosocomial infections; either event may prove fatal and ultimately be considered the cause of death (6).

During the COVID-19 pandemic in Jamaica, surveillance systems have been bolstered; the Ministry of Health and Wellness introduced broad community-based testing, many diagnostic laboratories have introduced real-time PCR testing, and the University of the West Indies has introduced next-generation techniques sequencing techniques for whole-genome sequencing of viruses. Further enhancing responses to emerging viruses, the University of the West Indies recently became a member of the Abbott Pandemic Defense Coalition that aims to increase virus surveillance and discovery (7). This increased infrastructure will likely improve surveillance for future viral epidemics in Jamaica.

References
1. Anzinger JJ, Mears CD, Ades AE, Francis K, Phillips Y, Leys YE, et al.; ZIKAction Consortium.1,2. Antenatal seroprevalence of Zika and chikungunya viruses, Kingston metropolitan area, Jamaica, 2017–2019. Emerg Infect Dis. 2022;28:473–5. https://doi.org/10.3201/eid2802.211849
2. Freitas ARR, Gérardin P, Kassar L, Donalisio MR. Excess deaths associated with the 2014 chikungunya epidemic in Jamaica. Pathogens and Global Health. 2019;113:27–31. https://doi.org/10.1080/20477724.2019.1574111
3. Evans-Gilbert T. Chikungunya and neonatal immunity: fatal vertically transmitted chikungunya infection. Am J Trop Med Hyg. 2017;96:913–5. https://doi.org/10.4269/ajtmh.16-0491
4. Sharp TM, Ryff KR, Alvarado L, Shieh W-J, Zaki SR, Margolis HS et al. Surveillance for chikungunya and dengue during the first year of chikungunya virus circulation in Puerto Rico. J Infect Dis. 2016;214(suppl_5):S475–81. https://doi.org/10.1093/infdis/jiw245
5. Freitas ARR, Donalisio MR, Alarçon-Elbal PM. Excess mortality and causes associated with chikungunya, Puerto Rico, 2014–2015. Emerg Infect Dis. 2018;24:2352–5. https://doi.org/10.3201/eid2412.170639

Address for correspondence: André Ricardo Ribas Freitas, School of Medicine San Leopoldo Mandic—Department of Social Medicine, R. Dr. José Rocha Junqueira, 13—Swift, Campinas, SP, São Paulo 13045-755, Brazil; email: andre.freitas@slmandic.edu.br

Joshua J. Anzinger
DOI: https://doi.org/10.3201/eid2808.221006
Author affiliations: The University of the West Indies, Kingston, Jamaica; The Global Virus Network Jamaica Affiliate, Kingston, Jamaica
To the Editor: Costello et al. described a patient in Maryland, USA, with a diffuse vesicular rash initially diagnosed as disseminated varicella zoster virus (VZV) infection. Only after a biopsy revealed unexpected findings was monkeypox suspected (1). Monkeypox is commonly confused with VZV in countries where both infections are endemic. High fever, lymphadenopathy, and a deep-seated, well-circumscribed, umbilicated rash in the same stage of development (i.e., macule, papule, vesicle, or scab) in distinct anatomic locations are characteristic of monkeypox (2). Although the patient in Maryland experienced lymphadenopathy and rash with umbilicated lesions suggestive of monkeypox, he was afebrile, denied other prodromal signs and symptoms (e.g., headache and chills) that typically precede monkeypox rash, and improved while receiving intravenous acyclovir, features more consistent with VZV. However, the unusual clinical signs and symptoms experienced by this patient were similar to those observed in other patients in the evolving 2022 multinational monkeypox response.

Because differential diagnosis can be challenging, public health authorities should be consulted promptly when monkeypox is possible. US Laboratory Response Network laboratories (https://emergency.cdc.gov/lrn) can enable rapid testing of specimens (e.g., lesions swab), and pathogen-specific antiviral medications can be acquired through consultation with the Centers for Disease Control and Prevention. Public health investigation for a single case of monkeypox can be intensive and complicated; case-patient contacts outside of the hospital must be identified, monitored, and potentially given 1 of the 2 orthopoxvirus vaccines offered for postexposure prophylaxis in the United States (3–5).

Factors that should raise suspicion for monkeypox in a patient with related signs and symptoms include history of travel outside of the United States to a country with confirmed cases or where monkeypox virus is endemic, contact with a person with a similar-appearing rash or who has received a diagnosis of confirmed or probable monkeypox, contact with Africa-endemic wild animal or pet species (living or dead), or use of a product derived from those animals (e.g., game meat, creams, lotions, powders). Monkeypox should also be considered in patients with close or intimate contact with persons in social networks experiencing high monkeypox activity, including men who have sex with men who meet partners through a website, digital application, or social event. Prompt consultation with public health authorities is essential for providing clinical guidance, expediting testing and treatment, and preventing secondary cases (3).

References

1. Costello V, Sowash M, Gaur A, Cardis M, Pasieka H, Wortmann G, et al. Imported monkeypox from international traveler, Maryland, USA, 2021. Emerg Infect Dis. 2022;28:1002–5. https://doi.org/10.3201/eid2805.220292
2. Osadebe L, Hughes CM, Shongo Lushima R, Kabamba J, Nguete B, Malekani J, et al. Enhancing case definitions for surveillance of human monkeypox in the Democratic Republic of Congo. PLoS Negl Trop Dis. 2017;11:e0005857. https://doi.org/10.1371/journal.pntd.0005857
3. Rao AK, Schulte J, Chen T-H, Hughes CM, Davidson W, Neff JM, et al.; July 2021 Monkeypox Response Team. Monkeypox in a traveler returning from Nigeria—Dallas, Texas, July 2021. MMWR Morb Mortal Wkly Rep. 2022;71:509–16. https://doi.org/10.15585/mmwr.mm7114a1
4. Petersen BW, Damon IK, Pertowski CA, Meaney-Delman D, Guarinzo JT, Beigi RH, et al. Clinical guidance for smallpox vaccine use in a postevent vaccination program. MMWR Recomm Rep. 2015;64(RR-02):1–26.
5. Rao AK, Petersen BW, Whitehill F, Razeeq JH, Isaacs SN, Merch linsky MJ, et al. Use of JYNNEOS (smallpox and monkeypox vaccine, live, nonreplicating) for preexposure vaccination of persons at risk for occupational exposure to orthopoxviruses: recommendations of the Advisory Committee on Immunization Practices—United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:734–42. https://doi.org/10.15585/mmwr.mm7112e1

Address for correspondence: Faisal Syed Minhaj, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop 24-12, Atlanta, GA 30327-4027, USA; email: fminhaj@cdc.gov